ArticleJournal of cardiovascular translational research2026
Correlation Between Serum GDF11 Levels and the Progression of Ischemic Mitral Regurgitation and Long-term Prognosis in Patients with ST-segment Elevation Myocardial Infarction After Percutaneous Coronary Intervention.
Article in Journal of cardiovascular translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Ischemic mitral regurgitation (IMR) commonly complicates pPCI in STEMI patients. GDF11, a protective cardiovascular factor, may influence IMR progression and prognosis. Among 310 STEMI patients, 126 with recent normal echocardiography underwent pPCI with pre-procedural GDF11 testing. Cox regression, ROC analysis, and Spearman's correlation assessed GDF11's predictive value for IMR exacerbation and cardiac function. Lower GDF11 predicted IMR worsening (HR = 0.982, P = 0.004; AUC = 0.744, P < 0.001). High GDF11 patients had reduced IMR progression (P = 0.0013) and heart failure risk (P = 0.0003). GDF11 correlated with LVEF and left atrial changes (P < 0.05). Serum GDF11 independently predicts IMR exacerbation and post-pPCI heart failure, serving as a prognostic biomarker in STEMI.
Indexed as
Identifiers
41642484What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.